Novavax stock surged 14.2% in premarket trading

Tiger Newspress2021-11-01

Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization of its COVID-19 vaccine in multiple countries and regions.

Novavax, Inc. today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.

In addition,Novavax have announced the completion of its rolling regulatory submission to the U.K.;

Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法